Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UniStar
NCT02968108Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of ustekinumab in Crohn's disease (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Serum Ustekinumab Concentrations Over Time. Started Jan 2017; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02968108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968108.